Orphan medicines: special treatment required?: case study 1: Afinitor and renal cell carcinoma
- Document type
- Case study
- Corporate author(s)
- 2020health (Think tank)
- Date of publication
- 1 November 2012
- Health Services
- Social welfare
- Material type
Download (138KB )
This case study on the drug Afinitor and treatment of renal cell carcinoma accompanies a report that examines the evidence to see if there are ways of improving decision making on treatments for people with rare diseases in the NHS. Afinitor (everolimus) is an anticancer medicine, manufactured by Novartis. Afinitor has been shown in clinical trials to reduce cancer cells in patients with renal cell carcinoma (RCC), and can lengthen life. RCC is a disease where cancer cells are found in particular tissues of the kidney. It is also known as cancer of the kidney or renal adenocarcinoma.
Afinitor was awarded orphan drug designation for its use in RCC, and approved for use by the European Medicines Agency in 2009. It has subsequently been removed from the Community Register of orphan medicinal products at the request of Novartis.
Related to Health Services
Variation in end of life hospital spending in England: evidence from linked survey and administrative data
Working Paper on healthcare spending
Report on shared measurement in the NHS
Report on human capital in India
Report on data-driven technologies in mental healthcare
Related to 2020health
This report uses literature data, observations and discussions to frame a new approach to understanding the nature and implications of health-system avoidance by individuals who choose to remain ignorant
This report finds that the over 65s made up 17% of the population in 2010, up from 15% in 1985, with projections indicating a rise to 23% by 2035.Exponential growth of an aging population indicates
This report by the Foresight Project aims to ensure that the optical sector is better equipped to understand directions in technology, ocular medical developments and demographics in the years up to 2030.
Current political, economic and social discourse on obesity in the UK illuminates the great complexities and myriad socio-economic considerations that inform people’s health, diets, and health seeking